Because acute myeloid leukemia moves quickly, it’s important to begin treatment right away. It will depend on several things, including what kind of AML you have, how far it’s spread, and your ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your ...

Cite this: Aging, Acute Myelogenous Leukemia, and Allogeneic Transplantation: Do They Belong in the Same Sentence? - Medscape - Aug 01, 2009. Abstract and Introduction ...

One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy-and an aggressive type ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis ...

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease ...

Study unveils key immune cells found to boost cancer treatment success in acute myeloid leukemia New computational tool aims to identify immune responses to cellular therapy in AML treatments Date ...

More information: Stefanie Weiss et al, Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia, Cancer Letters (2025). DOI: 10.1016/j.canlet.2025.217501 ...

CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nature Cancer, 2025; DOI: 10.1038/s43018-025-00934-1 ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid ...